<body><script type="text/javascript"> function setAttributeOnload(object, attribute, val) { if(window.addEventListener) { window.addEventListener('load', function(){ object[attribute] = val; }, false); } else { window.attachEvent('onload', function(){ object[attribute] = val; }); } } </script> <div id="navbar-iframe-container"></div> <script type="text/javascript" src="https://apis.google.com/js/platform.js"></script> <script type="text/javascript"> gapi.load("gapi.iframes:gapi.iframes.style.bubble", function() { if (gapi.iframes && gapi.iframes.getContext) { gapi.iframes.getContext().openChild({ url: 'https://www.blogger.com/navbar/1042626312146086864?origin\x3dhttp://medreader.blogspot.com', where: document.getElementById("navbar-iframe-container"), id: "navbar-iframe" }); } }); </script>

Blog Team

Archives

July 1, 2007

Potential cure for HIV discovered


CHICAGO (AFP) - In a breakthrough that could potentially lead to a cure for HIV infection, scientists have discovered a way to remove the virus from infected cells, a study released Thursday said
The scientists engineered an enzyme which attacks the DNA of the HIV virus and cuts it out of the infected cell, according to the study published in Science magazine.
The enzyme is still far from being ready to use as a treatment, the authors warned, but it offers a glimmer of hope for the more than 40 million people infected worldwide.
"A customized enzyme that effectively excises integrated HIV-1 from infected cells in vitro might one day help to eradicate (the) virus from AIDS patients," Alan Engelman, of Harvard University's Dana-Farber Cancer Institute, wrote in an article accompanying the study.
Current treatments focus on suppressing the HIV virus in order to delay the onset of AIDS and dramatically extend the life of infected patients.
What makes HIV so deadly, however, is its ability to insert itself into the body's cells and force those cells to produce new infection.
"Consequently the virus becomes inextricably linked to the host, making it virtually impossible to 'cure' AIDS patients of their HIV-1 infection," Engelman explained.
That could change if the enzyme developed by a group of German scientists can be made safe to use on people.
That enzyme was able to eliminate the HIV virus from infected human cells in about three months in the laboratory.
The researchers engineered an enzyme called Tre which removes the virus from the genome of infected cells by recognizing and then recombining the structure of the virus's DNA.
This ability to recognize HIV's DNA might one day help overcome one of the biggest obstacles to finding a cure: the ability of the HIV virus to avoid detection by reverting to a resting state within infected cells which then cease to produce the virus for months or even years.
"Numerous attempts have been made to activate these cells, with the hope that such strategies would sensitize the accompanying viruses to antiviral drugs, leading to virus eradication," Engelman wrote. "Advances with such approaches in patients have been slow to materialize."
New experiments must be designed to see if the Tre enzyme can be used to recognize these dormant infected cells, he wrote.
"Although favorable results would represent perhaps only a baby step toward eventual use in patients, the discovery of the Tre recombinase proves that enzymatic removal of integrated HIV-1 from human chromosomes is a current-day reality," he said.
The researchers who developed the enzyme were optimistic about their ability to design additional enzymes which would target other parts of the virus's DNA.
However they warned that there were significant barriers to overcome before the enzyme could be used to help cure patients.
"The most important, and likely most difficult, among these is that the enzyme would need efficient and safe means of delivery and would have to be able to function without adverse side effects," wrote lead author Indrani Sarkar of the Max Planck Institute for Molecular Cell Biology and Genetics in Dresden.

| Tags: Cancer, HIV and AIDS |

Labels: ,

June 28, 2007

UNAIDS Releases New Guidelines To Ensure Confidentiality Of People Living With HIV/AIDS


UNAIDS on Friday released new guidelines that aim to ensure that the confidentiality of people living with HIV/AIDS is not compromised when collecting and storing information about the disease, UN News Service reports. The guidelines were developed through a workshop supported by UNAIDS and the President's Emergency Plan for AIDS Relief (UN News Service, 6/22).

The guidelines, called the "Interim Guidelines on Protecting the Confidentiality and Security of HIV Information," provide principles, definitions and technical recommendations to maintain confidentiality, privacy and security when working with HIV-related information (UNAIDS release, 6/21). According to the guidelines, using information for public health purposes must be balanced against individual rights to privacy and confidentiality, UN News Service reports. The recommendations also include a call for countries to establish confidentiality and privacy laws to maintain that balance (UN News Service, 6/22).

"Good clinical information is required for optimum treatment and care for people living with HIV," Eddy Beck, a UNAIDS senior technical officer, said. He added, "Ensuring this information is securely stored and confidentiality maintained will avoid potential stigmatization and discrimination of individuals and communities, and enhance the quality of the information collected." According to UNAIDS, the guidelines will be field tested and additional training materials will be developed (UNAIDS release, 6/21).

| Tags: Breast Cancer, HIV and AIDS, Public Health and Safety |

Labels: , , ,

June 29, 2007

Cannabis Has "Clear Medical Benefits" For HIV Patients


Cannabis Has "Clear Medical Benefits" For HIV Patients, Study Says -- Smoked marijuana produces “substantial and comparable increases in food intake … with little evidence of discomfort and no impairment of cognitive performance”

Investigators at Columbia University in New York assessed the efficacy of inhaled cannabis and oral THC (Marinol) in a group of ten HIV-positive patients in a double-blind, placebo-controlled trial. All of the subjects participating in the study had prior experience using marijuana therapeutically and were taking at least two antiretroviral medications.

| Tags: HIV and AIDS |

Labels:

August 4, 2007

Abstinence Programs Don't Cut HIV Risk

Programs that stress sexual abstinence have had no impact on HIV infection rates in the U.S., according to a new research review. But an abstinence education expert says the study is flawed.

Investigators analyzed findings from 13 studies comparing abstinence-only education to other forms of sexual education or no sexual education at all. Some 16,000 preteens and teens in the U.S. participated in the self-reported studies.

"We found no evidence at all that these abstinence-only programs resulted in lower HIV infection rates for any targeted subgroup," researcher Paul Montgomery, DPhil, of the University of Oxford's Center for Evidence-Based Medicine, tells WebMD.

SOURSE - WebMed

| Tags: Addiction, Depression, HIV and AIDS |

Labels: , , ,